Evidence map›Paper›PMID 41542560›Full record

ArticlebioRxiv : the preprint server for biology2026

Latent Regulatory Programs Generate Synthetic T Cell States with Enhanced Therapeutic Potential.

Brandon M Pratt, Genevieve N Mullins, Nolan Brown, William D Green, Jennifer Modliszewski, Fucong Xie, Lara van Rooyen, Vasyl Zhabotynsky, Alexander N Jambor, Gabrielle Cannon and 12 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Brandon M PrattLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.ORCID 0000-0002-1509-7509
Genevieve N MullinsLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Nolan BrownLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
William D GreenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Jennifer ModliszewskiLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Fucong XieLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Lara van RooyenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Vasyl ZhabotynskyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Alexander N JamborDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA, USA.
Gabrielle CannonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Jarred M GreenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Andrew KennedyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Coral Del Mar Alicea PauntoLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Huitong ShiLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Emily MerrittLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Takeshi EgawaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-7489-1051
Ashwin SomasundaramLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Wei WangDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA, USA.
Jessica E ThaxtonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Gianpietro DottiLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
H Kay ChungLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.ORCID 0000-0002-7028-2432
J Justin MilnerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.ORCID 0000-0002-0752-2130

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5M
RESEARCH TRAINING IN ALLERGY AND CLINICAL IMMUNOLOGYT32AI007062 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David B. Peden, John W. Sleasman · 1985 to 2026
$6.1M
The transcription factor c-MYC in lymphocyte expansion and restriction of stemnessR01AI130152 · NIAID · WASHINGTON UNIVERSITY · PI Takeshi Egawa · 2017 to 2026
$4.6M
CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)T32CA196589 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Gaorav P. Gupta, ALEXANDER V KABANOV · 2015 to 2026
$4.5M
Epigenetic regulation of T cell differentiation during infectionR01AI177864 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI John Justin Milner · 2024 to 2026
$1.7M
Molecular Programming of CD8+ T Cell Accumulation and Activity in TumorsR00CA234430 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MILNER, JOHN JUSTIN · 2020 to 2022
$669k
Next-generation T cell therapy: SMARTER T cells for enhanced and durable anti-tumor immunityK01EB034321 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hokyung Kay Chung · 2023 to 2026
$639k
NCI NIH HHS P30 CA016086NCI NIH HHS R00 CA234430NCI NIH HHS T32 CA196589NIAID NIH HHS R01 AI130152NIAID NIH HHS R01 AI177864NIAID NIH HHS T32 AI007062NIBIB NIH HHS K01 EB034321NIDDK NIH HHS P30 DK034987NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

Transcription factors (TFs) govern cell fate through coordinated gene-regulatory networks, yet the full potential of these networks to generate non-native, therapeutically advantageous cell states

Identifiers

PMID41542560
PMCPMC12803213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.